NTT Biopharma PIPELINE

Platform Technologies

Brain Delivery Ocular Delivery (Eyedrop Nanoformulation) Nucleic Acid Delivery Oral Peptide Delivery Active Targeting Nanoparticle

Brain Disease

NTT-001 DNA Plasmid (IV Injection for PD)

Cancer Therapy

NTT-002

Ocular Disease

NTT-003 (Eyedrop Formulation for Wet-AMD) ASO (Eyedrop Formulation for Wet-AMD) Therapeutic Peptide (Eyedrop Formulation for Dry-AMD)

ASO (Eyedrop Formulation)

Summary

• MSN eyedrop formulations loaded with antisense oligonucleotides (ASOs) enable efficient delivery to the posterior segment of the eye and demonstrate superior gene-silencing efficacy.

• An anti-VEGF ASO delivered via MSN eyedrop formulation significantly reduces choroidal neovascularization in a wet-AMD animal model.

Efficient ASO Delivery to the Backside of the Eye

Efficacy in Inhibiting Neovascularization